A Novel Pyroptosis-Associated Long Noncoding RNA Signature to Predict the Prognosis of Patients with Colorectal Cancer

Abstract

Purpose Pyroptosis plays an important role in tumor progression. However, there is no pyroptosis-associated long noncoding RNA (lncRNA) signature to predict the prognosis of patients with colorectal cancer (CRC). Materials and Methods The RNA sequencing data (RNA-seq) and corresponding clinical information relating to CRC patients were obtained from the Cancer Genome Atlas (TCGA) database and the GSE39582 dataset. Univariate Cox regression analysis was used to identify pyroptosis-associated lncRNAs linked to CRC prognosis. Subsequently, multivariate Cox regression analysis was performed to construct a pyroptosis-associated lncRNAs signature within the TCGA cohort, which was then validated using the GSE39582 dataset. We used Kaplan–Meier (K-M) analysis, principal component analysis (PCA), and receiver operating characteristic curve (ROC) analysis to evaluate our novel lncRNA signature. Finally, gene set enrichment analysis (GSEA) was performed to explore the potential function of the lncRNA signature. Results We constructed a pyroptosis-associated lncRNA signature comprising four lncRNAs (ELFN1-AS1, PCAT6, TNRC6C-AS1, and ZEB1-AS1). CRC patients were subdivided into high- and low-risk groups based on median risk scores. The results of the K-M, PCA, and ROC analyses showed that this signature could accurately predict the prognosis of CRC patients. Univariate and multivariate Cox regression analyses showed that the pyroptosis-associated signature was an independent prognostic factor. Functional analysis suggested that tumor-associated pathways were enriched for in the high-risk CRC patient group. Conclusion Our study established an effective prognostic signature for CRC patients that may represent a potential therapeutic target.

Construction of a pyroptosis-related lncRNAs signature for predicting prognosis and immunotherapy response in glioma

“…Recent studies suggest that the PRLS is satisfactory in predicting the prognosis of several cancers. [ 21 , 23 , 24 , 40 ] These studies provide new clues for further research on the role of PRlncRNAs in cancer.…”

“…Previous evidence has found that PRlncRNAs are linked to tumor progression, prognosis, and immune status. [21][22][23][24] However, little is known about the function and mechanism of these small molecules in glioma.…”

A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity

“…It has been shown that lncRNAs can mediate cellular pyroptosis through certain mechanisms and further act on cancer cells. Many investigations have been conducted to establish the signature of PRlncRNAs to predict the prognosis of tumor patients in breast ( Lv et al, 2021 ; Ping et al, 2021 ), ovarian ( Tan et al, 2021 ), melanoma ( Wu L. et al, 2021 ), lung ( Lin et al, 2021 ), endometrial ( Chen et al, 2021 ), liver cancers ( Wu Z. H. et al, 2021 ) etc., but they have rarely been found in GC. Therefore, we started to establish a validated PRlncRNAs biomarker to predict the survival status and treatment outcome of GC patients.…”

Role of long non-coding RNA ELFN1-AS1 in carcinogenesis

“…The risk signature performed better in the prediction of one-year OS. Sijun Chen et al [ 85 ] developed a prognostic signature of four pyroptosis-related lncRNAs in CRC. Pyroptosis is a form of inflammatory cell death triggered by inflammasomes [ 86 ].…”